Similarly, a prospective cohort study of the German Glioma Network of 233 glioblastoma patients aged ≥ 70 years revealed longer PFS (5.2 vs. 4.7 months) and OS (8.4 vs. 6.4 months) in patients with MGMT promoter-methylated tumours (Reifenberger et al. 2012). This evidence concerns the gene MGMT and glioma.